References
- Zabora J, Brintzenhofe-Szoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology 2001;10:19–28.
- Michallet A-S, Coiffier B. Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 2009;23:11–23.
- Rueda A, Sabin P, Llanos M, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematol Oncol 2008;26:27–32.
- Aguiar Bujanda D, Aguiar Morales J, Bohn Sarmiento U, Saura Grau S, Rodriguez Franco C. Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. Clin Transl Oncol 2009;11:604–608.
- Tadmor T, McLaughlin P, Polliack A. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? Leuk Lymphoma 2010;51:737–738.
- Tholstrup D, Brown P, Jurlander J, Jeppesen P, Groenvold M. Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily. Leuk Lymphoma 2011;52:400–408.
- Cheung M, Haynes A, Meyer R, Stevens A, Imrie K; Members of the Hematology, Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev 2007;33:161–176.
- Hornberger J, Best J. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005;103:1644–1651.
- Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality of life instruments: attributes and review criteria. Qual Life Res 2002;11:193–205.
- Luckett T, King M, Butow P, Friedlander M, Paris T. Assessing health-related quality of life in gynecologic oncology. Int J Gynecol Cancer 2010;20:664–684.
- Aaronson N, Ahmedzai S, Berman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
- Kemmler G, Holsner B, Kopp M, et al. Comparison of two quality of life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol 1999;17:2932–2940.